This blog is still in BETA
We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.
This blog is still in BETA
We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, you may find duplicate stories, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.
Capital Public Radio News
Gilead's lead drug, hepatitis C fighter Sovaldi, came in almost $300 million below consensus, at $2.8 billion. Its HIV drugs all outperformed, more than making up the difference. Apart from Sovaldi, Gilead's product sales grew 8% sequentially. Sovaldi ...»
from HCV - Google News http://ift.tt/135Nsgq via IFTTT
ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL
MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989
The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.
Find us on Facebook
Stay in the debate! Join our discussion group!
Stay up to date! Join the mailing list!
Powered by Squarespace
